Patient-Derived Acellular Ascites Fluid Affects Drug Responses in Ovarian Cancer Cell Lines Through the Activation of Key Signalling Pathways

Impact of Patient-Derived Acellular Ascites on Drug Responses in Ovarian Cancer Cell Lines Through Activation of Key Signaling Pathways Background Ovarian cancer is one of the deadliest gynecological malignancies, with a 5-year survival rate of only 30% for patients with advanced epithelial ovarian cancer (EOC). Although surgery and chemotherapy (e...

PRDX5 and PRDX6 Translocation and Oligomerization in Bull Sperm: A Response to Cryopreservation-Induced Oxidative Stress

PRDX5 and PRDX6 in Oxidative Stress Response During Cryopreservation of Bull Sperm Academic Background Cryopreservation is a critical step in animal breeding and assisted reproductive technologies, particularly in the preservation of bull sperm. However, oxidative stress generated during cryopreservation significantly reduces sperm quality, leading...

Metabolic Imaging Distinguishes Ovarian Cancer Subtypes and Detects Their Early and Variable Responses to Treatment

Metabolic Imaging Distinguishes Ovarian Cancer Subtypes and Detects Their Early and Variable Responses to Treatment Academic Background Ovarian cancer is one of the leading causes of cancer-related deaths in women, with high-grade serous ovarian cancer (HGSOC) being the most common lethal subtype. In recent years, metabolic subtypes have been ident...

SPTLC2 Drives an EGFR-FAK-HBEGF Signaling Axis to Promote Ovarian Cancer Progression

SPTLC2 Drives an EGFR-FAK-HBEGF Signaling Axis to Promote Ovarian Cancer Progression Academic Background Ovarian cancer (OC) is one of the most lethal cancers in the female reproductive system, with complex pathogenesis and limited treatment options. The epidermal growth factor receptor (EGFR) signaling pathway is widely dysregulated in various can...

Patterns of Genomic Instability in Ovarian Cancer Patients

Background and Research Question Ovarian cancer, as a fatal gynecological malignancy, has become the focus of recent studies, particularly on expanding the feasibility of targeted therapies. The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors has marked a groundbreaking treatment option for ovarian cancer, especially for patients with...